Vaxcyte, Inc. (PCVX)
NEUTRALFundamental
37
Preço
$61.31
Capitalização de Mercado
$9.16B
Parte 1 · Quanto vale a empresa
Visão Geral
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
0
Exercício encerrado em 31/12/2025
Resultado Líquido
$-767M
Exercício encerrado em 31/12/2025
Fluxo de Caixa Livre
$-669M
Capital Próprio Total
$2.69B
Passivo Total
$317M
Rácio de Liquidez
5.72
Cobertura de Juros
-
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$109.00
Preço Atual
$61.31
Margem de Segurança
+43.8%
Intervalo de Valor Justo
$103.55 - $114.45
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-28.5%
Rácio P/B
3.34
P/FCF
-
Margem Bruta
-
ROIC
-32.1%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
11.2%
ROIC − WACC
-43.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (6)
- EPS shows upward trend
- Price CAGR 15.36%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 88% Buy
Reprovado (9)
- ROIC -32.1%
- P/B Ratio 3.34
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -37.6%
- Earnings Surprise avg -14.9%
- Share Dilution 11.5%
- Piotroski F-Score 1/9
Indisponível (12)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A emitir novas ações, diluindo a participação
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 57 |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO | 57 |
| Mr. James T. Wassil M.B.A., M.S. | Executive VP & COO | 56 |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 43 |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer | 52 |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | 61 |
| Ms. Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Jeff Macdonald | Executive Director of Investor Relations | - |
| Ms. Whitney Jones | Chief People Officer | - |
| Ms. Janet Graesser | Senior Vice President of Corporate Affairs | - |
Risco de Auditoria
3
Risco do Conselho
6
Risco de Remuneração
8
Risco dos Direitos dos Acionistas
8
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for PCVX, sourced from Markets Gazette.